1-m-tolyl-4-(3,4,5-trimethoxybenzyl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-m-tolyl-4-(3,4,5-trimethoxybenzyl)piperazine
• 英文别名: 1-(3-Methylphenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]piperazine
• 化学式: C₂₁H₂₈N₂O₃
• 分子量: 356.465
• InChiKey: IKWIHGDLBMWYDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  34.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors
  申请人：Pfizer Products Inc.

  公开号：EP1201268A2

  公开（公告）日：2002-05-02

  The present invention relates to a method of treating dementia or cognitive deficits associated with Alzheimer's Disease or Parkinson's Disease in a mammal, including a human, by administering to the mammal a D4 dopamine receptor antagonist in combination with an acetylcholine esterase inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 dopamine receptor antagonist and an acetylcholine esterase inhibitor.

  本发明涉及一种治疗与阿尔茨海默病或帕金森病相关的哺乳动物（包括人类）痴呆症或认知缺陷的方法，其方法是向哺乳动物施用 D4 多巴胺受体拮抗剂与乙酰胆碱酯酶抑制剂。它还涉及含有药学上可接受的载体、D4多巴胺受体拮抗剂和乙酰胆碱酯酶抑制剂的药物组合物。
• Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
  申请人：Pfizer Products Inc.

  公开号：EP1213031A2

  公开（公告）日：2002-06-12

  The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.

  本发明涉及一种治疗哺乳动物（包括人类）抑郁症、焦虑症或精神病的方法，其方法是向哺乳动物施用 D4 受体拮抗剂与抗抑郁剂或抗焦虑剂。它还涉及含有药学上可接受的载体、D4 受体拮抗剂和抗抑郁剂或抗焦虑剂的药物组合物。
• Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
  申请人：——

  公开号：US20020052373A1

  公开（公告）日：2002-05-02

  The present invention relates to a method of treating dementia or cognitive deficits associated with Alzheimer's Disease or Parkinson's Disease in a mammal, including a human, by administering to the mammal a D4 dopamine receptor in combination with an acetylcholine esterase inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 dopamine receptor and an acetylcholine esterase inhibitor.

  本发明涉及一种治疗与阿尔茨海默病或帕金森病相关的哺乳动物（包括人类）痴呆症或认知缺陷的方法，其方法是向哺乳动物施用 D4 多巴胺受体与乙酰胆碱酯酶抑制剂。它还涉及含有药学上可接受的载体、D4 多巴胺受体和乙酰胆碱酯酶抑制剂的药物组合物。
• Combination treatment for depression, anxiety and psychosis
  申请人：Pfizer Inc

  公开号：US20020094986A1

  公开（公告）日：2002-07-18

  The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.

  本发明涉及一种治疗哺乳动物（包括人类）抑郁症、焦虑症或精神病的方法，其方法是向哺乳动物施用 D4 受体拮抗剂与抗抑郁剂或抗焦虑剂。它还涉及含有药学上可接受的载体、D4 受体拮抗剂和抗抑郁剂或抗焦虑剂的药物组合物。
• US4370330A
  申请人：——

  公开号：US4370330A

  公开（公告）日：1983-01-25